An Open Label, Phase I Study to Assess the Effect of Itraconazole (CYP3A4 and P-gp Inhibitor) on the Pharmacokinetics of Anetumab Ravtansine and to Assess the ECG Effects, Safety and Immunogenicity of Anetumab Ravtansine Given as a Single Agent and Together With Itraconazole in Subjects With Mesothelin-expressing Advanced Solid Cancers
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Anetumab ravtansine (Primary) ; Itraconazole
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colon cancer; Fallopian tube cancer; Gastric cancer; Malignant thymoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 23 Aug 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2019 Planned End Date changed from 28 Jun 2019 to 19 Jul 2019.
- 24 Sep 2018 Planned End Date changed from 2 Nov 2018 to 28 Jun 2019.